Industry corner: perspectives and controversiesBlinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL)
Under an Elsevier user license
open archive
Cited by (0)
Copyright © 2017 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.